CAR T-REX CAR T cells Rewired to prevent EXhaustion in the tumour microenvironment
- Coordinator
- Stemmatters, Biotecnologia E Mediciina Regenerativa SA, Portugal
- Runs
- 1 April 2023 to 30 June 2027
- Status
- Running
- EU funding
- €2.7m
- Total cost
- €2.7m
- Partners
- 6 organisations in 5 countries
- Type
- European Innovation Council
- Grant agreement
- 101099867
What the project is doing
In the project's own words, from its summary on CORDIS.
Although immunotherapy of select hematological malignancies using Chimeric Antigen Receptor (CAR) redirected T lymphocytes has recently gained regulatory approval, successful treatment of solid tumors using CAR T cells remains elusive. One salient problem is the limited efficacy and untimely exhaustion of CAR T cells in the tumor microenvironment (TME). Combining innovative methods of genome editing, chemistry and immunology, CAR T-REX proposes to explore a novel concept of building auto-regulated genetic circuits into CAR T cells to selectively circumvent their exhaustion upon activation in the TME.
Genetic rewiring will be achieved by precisely inserting artificial miRNAs under endogenous exhaustion-related “Driver” promoters to downregulate “Target” genes that cause exhaustion. Proprietary technology enables specific replacement of the “Driver” gene without risking off-target mutations. Further advantages of combined insertion and silencing are (i) the ability to regulate when a gene is turned on/off by biologically and clinically relevant cellular cues, and (ii) multiple gene-knockdown with a single dsDNA cleavage and RNA-silencing of both alleles.
These genetic modifications will be implemented using a novel high-performance peptide-based gene delivery platform with unlimited loading capacity, allowing combination of several types of cargo, as well as economical large scale GMP production. Rewired HER2/Neu (ErbB2) redirected CAR T cells will be tested on preclinical breast and gastric carcinomas, and variants that eliminate tumors resistant to conventional 2nd and 3rd generation peers (without adverse events) will be developed/manufactured following quality-by-design principles under GMP-like conditions, thus accelerating the pathway towards clinical translation.
These approaches will also constitute a proof-of-concept for modifying therapeutic cell products, with the potential to considerably improve their safety, specificity, efficacy, scalability and cost.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Stemmatters, Biotecnologia E Mediciina Regenerativa SA | Barco Gmr | Portugal | Coordinator |
| Stiftung Leibniz-Institut Fur Immuntherapie | Regensburg | Germany | Participant |
| Universidad De Santiago De Compostela | Santiago De Compostela | Spain | Participant |
| Debreceni Egyetem | Debrecen | Hungary | Associatedpartner |
| Debreceni Egyetem | Debrecen | Hungary | Participant |
| Targetgene Biotechnologies Ltd | Rehovot | Israel | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI